Nonsteroidal anti-inflammatory drugs: Practical and theoretical considerations in their selection

American Journal of Medicine

Volumn 100, Issue 2 A, 1996, Pages 31S-36S

  Polisson, Richard ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; CLINICAL FEATURE; CONFERENCE PAPER; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; PATIENT MONITORING; PATIENT SELECTION; PEPTIC ULCER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ALGORITHM; DIGESTIVE SYSTEM; DRUG EFFECT; REVIEW; RISK FACTOR;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIGESTIVE SYSTEM; HUMANS; RISK FACTORS;

EID: 0029993460     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(97)89544-7     Document Type: Conference Paper

References (29)

1. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rheum. 1995;38:5-18.
2. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med. 1994;96:274-281.
3. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med. 1993;95(suppl 2A):40S-44S.
4. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal antiinflammatory drugs. J Biol Chem. 1993;268:6610-6614.
5. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1994;90:11693-11697.
6. Goodman TA, Simon LS. Minimizing the complications of NSAID therapy. J Musculoskel Med. 1994;11:33-46.
7. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk of peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
8. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991;114:307-319.
9. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-222.
10. Armstrong CP, Blower Al. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28:527-532.
11. Estes LL, Fuhs DW, Heaton AH, Butwinick CS. Gastric ulcer perforation associated with the use of injectable ketorolac. Ann Pharmacother. 1993;27:42-43.
12. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology. 1993;105:1078-1088.
13. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinftammatory drug use. Gastroenterology. 1989;96:647-655.
14. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Arthritis Rheum. 1994;37:1-9.
15. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1990;324:1043-1048.
16. Isenberg J, McQuaid KR, Laine L, Rubin W. Acid-peptic disorders. In: Yamada T, ed. Textbook of Gastroenterology. Philadelphia: JB Lippincott, 1991:1241-1324.
17. Laine L, Marin-Sorensen M, Weinstein WM. Nonsteroidal antiinflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol. 1992;87:1398-1402.
18. Kim JG, Graham DY, Misoprostol Study Group. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol. 1994;89:203-207.
19. Thillainayagam AV, Tabaqchali S, Warrington SJ, Farthing MJG. Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers. Dig Dis Sci. 1994;39:1085-1089.
20. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331:1675-1679.
21. Gabriel SE, Jakimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of NSAID. A meta-analysis. Ann Intern Med. 1991;115:787-796.
22. Langman MJS. Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med. 1988;84(suppl 2A):15S-19S.
23. Flynn BL. Rheumatoid arthritis and osteoarthritis: current and future therapies. Am Pharm. 1994;NS34:31-39.
24. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665-1670.
25. Walt RP. Drug therapy: misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med. 1992;327:1575-1580.
26. Ballinger AB, Kumar PJ, Scott DL. Misoprostol in the prevention of gastroduodenal damage in rheumatology. Ann Rheum Dis. 1992;51:1089-1093.
27. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123; 241-249.
28. Simon LS, Polisson RP, Hatoum H, Bittman RM. Patients who are at risk for an NSAID-induced serious gastrointestinal (GI) adverse event and the risk-reduction effect of misoprostol (Abstr.) Arthritis Rheum. 1995;38(suppl):S206.
29. Robinson MG, Griffin JW, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 1989;34:424-428.